Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intermittent hypoxia ameliorates behavioral deficits and exerts neurorestoration in a mouse photothrombotic stroke model.

Theranostics·2026
Same author

Dendrobium officinale leaf extract extends the mean lifespan in Caenorhabditis elegans via the DAF-16/SOD-3 axis.

Biogerontology·2026
Same author

HepaCopilot: A 6G-Enabled Multimodal Vision-Language Agent for Real-Time Hepatocellular Carcinoma Risk Stratification via Contrast-Enhanced Ultrasonography with Chain-of-Thought Clinical Reasoning.

IEEE journal of biomedical and health informatics·2026
Same author

Conjugation-Mediated Detoxification and Reactive Metabolite Risks in Microbial Degradation of a Cyano-Liquid Crystal Monomer.

Environmental science & technology·2026
Same author

Metabolic profiling reveals pyrimidine synthesis enzyme CAD as a central carbon metabolism signaling node in cancer cell proliferation.

Molecular cell·2026
Same author

Reply.

Ophthalmology·2026

Related Experiment Video

Updated: May 12, 2026

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

Generation of Bispecific Antibodies Using FAST-Ig™.

Chiew Ying Yeo1, Shu Feng2

  • 1Research Division, Chugai Pharmabody Research Pte Ltd, Singapore, Singapore. yeo.cy@chugai-pharmabody.com.

Methods in Molecular Biology (Clifton, N.J.)
|May 10, 2026
PubMed
Summary

This study introduces FAST-Ig™, a novel technology for robust bispecific antibody (BsAb) generation. FAST-Ig™ ensures preferential pairing, simplifying purification and enhancing BsAb production for research and manufacturing.

Keywords:
Bispecific antibodiesFAST-IgTMIon exchange chromatographyKnobs-into-holesSingle-cell expression

More Related Videos

Generation of Murine Monoclonal Antibodies by Hybridoma Technology
09:42

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Related Experiment Videos

Last Updated: May 12, 2026

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

Generation of Murine Monoclonal Antibodies by Hybridoma Technology
09:42

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Area of Science:

  • Biotechnology
  • Immunology
  • Protein Engineering

Background:

  • Bispecific antibodies (BsAbs) are crucial for research and manufacturing but face challenges in yield and purification due to random chain assembly.
  • Existing methods for improving BsAb production often require common light chains, extensive Fv engineering, or complex processing.

Purpose of the Study:

  • To present a novel engineering technology, FAST-Ig™, for efficient and preferential assembly of bispecific antibodies.
  • To provide a detailed protocol for generating and purifying IgG-like BsAbs using FAST-Ig™ and knobs-into-holes technology.

Main Methods:

  • Development of the FAST-Ig™ (four-chain assembly by electrostatic steering technology-immunoglobulin) system for preferential heavy and light chain pairing.
  • Co-expression of engineered parental monoclonal antibodies in single host cells.
  • Purification of BsAbs using ion exchange chromatography to remove residual mispaired antibodies.
  • Integration of FAST-Ig™ with knobs-into-holes technology for enhanced BsAb generation.

Main Results:

  • FAST-Ig™ technology enables preferential cognate heavy/light chain and heavy/heavy chain pairing in co-expressed antibodies.
  • The system significantly simplifies downstream processing by minimizing mispaired antibody formation.
  • Highly purified bispecific antibodies can be obtained efficiently.

Conclusions:

  • FAST-Ig™ offers a robust and streamlined approach for the generation of bispecific antibodies in single-cell expression systems.
  • This technology addresses key limitations in current BsAb production, facilitating their broader application in clinical and preclinical studies.
  • The provided protocols enable systematic generation and characterization of high-purity BsAbs.